Recognizing and Treating Tardive Dyskinesia with Once Daily Ingrezza (Valbenazine) Capsules
Erika Giraldo DNP, PMHNP
Tardive Dyskinesia (TD) may be more common than previously considered. The clinical prevalence of TD may be underestimated. The increased use of antipsychotics put patients at risk of developing TD. It is important for providers to be aware of TD symptoms as there are now FDA approved treatments for TD. Ingrezza is indicated for the treatment of adults with TD.
This presentation, Erika Giraldo, DNP, PMHNP, will discuss disease state of TD and the FDA approved treatment with Ingrezza. She will also present information to help you differentiate between movement disorders such as Parkinson’s, Akasthisia and TD.
Interested In Attending This Event?
Additional Registration Information:
Please complete the registation information to reserve your space at the dinner program. Each person attending must complete the registration.